CS
TMBR

Credit Suisse’s Timber Pharmaceuticals, Inc. TMBR Stock Holding History

Credit Suisse’s Portfolio TMBR Stock Details TMBR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-3
Closed -$11K – 4061
2018
Q2 		$11K Hold
3
– – ﹤0.01% 3938
2018
Q1 		$12K Buy
+3
New +$8.89K ﹤0.01% 3933

Other funds holding TMBR

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Credit Suisse's TMBR Position: Q3 2018 in Review

Credit Suisse sold out of Timber Pharmaceuticals, Inc. (TMBR) in Q3 2018, closing a stake of 3 shares — an estimated $11K sold.

Credit Suisse first reported a position in TMBR in Q1 2018 and held it in 2 quarters. The position peaked at $12K in Q1 2018. 22 funds tracked by Wall St. Rank hold TMBR as of Q3 2018.

  • Credit Suisse reported no remaining Timber Pharmaceuticals, Inc. position as of Q3 2018 after selling out during the quarter.
  • Credit Suisse sold 3 Timber Pharmaceuticals, Inc. shares in Q3 2018, an estimated $11K.
  • Credit Suisse first reported a position in Timber Pharmaceuticals, Inc. in Q1 2018 and held it in 2 quarters.
  • Credit Suisse's Timber Pharmaceuticals, Inc. position peaked at $12K in Q1 2018.
  • 22 funds tracked by Wall St. Rank held Timber Pharmaceuticals, Inc. as of Q3 2018.

Based on Credit Suisse's 13F filing for Q3 2018, filed 13 Nov 2018.